Kodiak is a binary retinal-biotech redemption story: breakthrough durability could unlock major upside, but trial failure, safety issues, or dilution could severely impair capital.
Overview
Kodiak Sciences is a precommercial retinal-disease biotech built around its Antibody Biopolymer Conjugate platform, designed to extend ocular drug durability and reduce injection burden. Its lead assets—Zenkuda, KSI-501, and KSI-101—target wet AMD, diabetic retinopathy, RVO, and inflammatory macular edema. Positive GLOW2 Phase 3 data revived Zenkuda’s prospects, but the company has no revenue, depends on upcoming binary trials, and faces intense competition from entrenched blockbuster therapies.